Healthcare Business Update: St. Jude Delayed Warning, Glaxo Makes Promise

St. Jude Medical (NYSE:STJ) waited until December 2010, to send doctors a warning in regards to insulation problems with the wires used with its Riata defibrillators, which was at least five years after the firm initially encountered the flaws, and two years subsequent to an internal audit that specifically identified the issue, according to the Wall Street Journal. Riata was finally withdrawn in 2011.

GlaxoSmithKline (NYSE:GSK) is breaking new ground in its promise to make detailed data from its clinical trials available to other researchers, beginning at the start of 2011. The pledge comes three months following its agreement to shell out a record $3 billion fine in the United States for giving misleading information on certain drugs.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

The safety of Pfizer’s (NYSE:PFE) ALO-02 capsules for the treatment of patients suffering moderate-to-severe chronic, non-cancer pain, has been certified by a long-term Phase III study. The “adverse event profile” was as anticipated, with the most common side effects being constipation, nausea, vomiting and headache, in more than 10 percent of the 395 patients involved in the study.

Shares of Amicus Therapeutics (NASDAQ:FOLD) pop on word that a preliminary study of its treatment for Pompe disease showed positive results. AT2220-enzyme replacement therapy co-administration boosted pompe enzyme activity in first three dose cohorts in the phase 2 study.

Don’t Miss: Has GlaxoSmithKline Put its Secretive Past to Bed?